Steerable Induction of the Thymosin β4/MRTF-A Pathway via AAV-Based Overexpression Induces Therapeutic Neovascularization.

Ziegler T, Kraus M, Husada W, Gesenhues F, Jiang Q, Pinkenburg O, Trenkwalder T, Laugwitz KL, le Noble F, Weber C, Kupatt C, Hinkel R

Human gene therapy3 Oct 2017Cited by 11 (Europe PMC)

PMID28726522PMCIDPMC12199625DOI10.1089/hum.2017.013PepBankPUB-28726522

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome
In rabbits with hindlimb ischemia, temporary (tet-off) AAV-driven Tβ4 expression improved capillary density in the ischemic hindlimb.
In plain wordsIn rabbits with limb ischemia, a virus that switches Tβ4 gene activity on for a short time raised tiny blood vessel density in the limb.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseCapillary density, rabbit hindlimb ischemia
Study
rabbitn: not reported in source
Hindlimb ischemia
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
In the model of rabbit hindlimb ischemia, temporary (tet-off) expression of Tβ4 improved capillary density, collateralization, and perfusion in the ischemic hindlimb, with no detectable difference to constitutive Tβ4 overexpression.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study compares AAVs encoding either constitutively active CMV or tet-off promoter regions in the preclinical models of hindlimb and chronic myocardial ischemia.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2872652201
02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome
In rabbits with hindlimb ischemia, temporary (tet-off) AAV-driven Tβ4 expression improved collateralization in the ischemic hindlimb.
In plain wordsIn rabbits with limb ischemia, a virus that switches Tβ4 gene activity on for a short time improved bypass vessel growth in the limb.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseCollateralization, rabbit hindlimb ischemia
Study
rabbitn: not reported in source
Hindlimb ischemia
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
In the model of rabbit hindlimb ischemia, temporary (tet-off) expression of Tβ4 improved capillary density, collateralization, and perfusion in the ischemic hindlimb, with no detectable difference to constitutive Tβ4 overexpression.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study compares AAVs encoding either constitutively active CMV or tet-off promoter regions in the preclinical models of hindlimb and chronic myocardial ischemia.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2872652202
03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome
In rabbits with hindlimb ischemia, temporary (tet-off) AAV-driven Tβ4 expression improved perfusion in the ischemic hindlimb.
In plain wordsIn rabbits with limb ischemia, a virus that switches Tβ4 gene activity on for a short time improved blood flow in the limb.
Peptide
Thymosin beta-4 (human)
Outcome
IncreasePerfusion, rabbit hindlimb ischemia
Study
rabbitn: not reported in source
Hindlimb ischemia
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
In the model of rabbit hindlimb ischemia, temporary (tet-off) expression of Tβ4 improved capillary density, collateralization, and perfusion in the ischemic hindlimb, with no detectable difference to constitutive Tβ4 overexpression.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study compares AAVs encoding either constitutively active CMV or tet-off promoter regions in the preclinical models of hindlimb and chronic myocardial ischemia.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2872652203
04AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome
In rabbits with hindlimb ischemia, temporary (tet-off) Tβ4 expression showed no detectable difference from constitutive Tβ4 overexpression.
In plain wordsIn rabbits with limb ischemia, short-term and constant Tβ4 gene activity showed no detectable difference.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeTemporary versus constitutive Tβ4 expression, rabbit hindlimb
Study
rabbitn: not reported in source
Hindlimb ischemia
Comparator
Constitutive Tβ4 overexpression
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
with no detectable difference to constitutive Tβ4 overexpression.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study compares AAVs encoding either constitutively active CMV or tet-off promoter regions in the preclinical models of hindlimb and chronic myocardial ischemia.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2872652204
05AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome
In pigs with chronic myocardial ischemia, constitutive Tβ4 expression for 4 weeks induced capillary growth.
In plain wordsIn pigs with poor heart blood flow, 4 weeks of constant raised Tβ4 gene activity increased tiny blood vessel growth.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseCapillary growth, pig chronic myocardial ischemia
Study
pign: not reported in source
Chronic myocardial ischemia
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
In the pig model of chronic myocardial ischemia constitutive expression of Tβ4 for 4 weeks induced capillary and collateral growth similarly to a pulsed expression (2 day expression per week for 3 weeks).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study compares AAVs encoding either constitutively active CMV or tet-off promoter regions in the preclinical models of hindlimb and chronic myocardial ischemia.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2872652205
06AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome
In pigs with chronic myocardial ischemia, constitutive Tβ4 expression for 4 weeks induced collateral growth.
In plain wordsIn pigs with poor heart blood flow, 4 weeks of constant raised Tβ4 gene activity increased bypass vessel growth.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseCollateral growth, pig chronic myocardial ischemia
Study
pign: not reported in source
Chronic myocardial ischemia
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
In the pig model of chronic myocardial ischemia constitutive expression of Tβ4 for 4 weeks induced capillary and collateral growth similarly to a pulsed expression (2 day expression per week for 3 weeks).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study compares AAVs encoding either constitutively active CMV or tet-off promoter regions in the preclinical models of hindlimb and chronic myocardial ischemia.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2872652206
07AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome
In pigs with chronic myocardial ischemia, constitutive Tβ4 expression induced capillary and collateral growth similarly to pulsed expression.
In plain wordsIn pigs with poor heart blood flow, constant raised Tβ4 gene activity grew vessels about as much as pulsed gene activity.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changePulsed versus constitutive Tβ4 expression, pig myocardium
Study
pign: not reported in source
Chronic myocardial ischemia
Comparator
Pulsed Tβ4 expression
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
similarly to a pulsed expression (2 day expression per week for 3 weeks).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study compares AAVs encoding either constitutively active CMV or tet-off promoter regions in the preclinical models of hindlimb and chronic myocardial ischemia.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2872652207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.